Key findings include the EMBODY trial’s demonstration of empagliflozin’s improvement in heart rate variability [22], and studies from Taiwan [23] and the SGLT2-I AMI PROTECT [24] indicating a 17% reduction in new arrhythmias and fewer severe arrhythmic events among SGLT2i users, respectively. This evidence concerns the gene SLC5A2 and cardiac arrhythmia.